EGFR and neoplasm: Li et al. prepared lipid-containingNPs loaded with anti-EGFR DNA aptamer, which can make NDDS reach the target cells more easily by exploiting the specific binding of EGFR DNA aptamer, thus increasing the drug concentration and exerting better anti-tumor efficacy of targeted drugs (Li et al., 2017).